146 related articles for article (PubMed ID: 26416471)
1. Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Gori A; Doroana M; Chernova O; Rockstroh JK; Banhegyi D; Bergin C; Verucchi G; Liu C; DeMasi R; Hadacek B; Nelson M
J Infect; 2015 Dec; 71(6):675-82. PubMed ID: 26416471
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Montes ML; Nelson M; Girard PM; Sasadeusz J; Horban A; Grinsztejn B; Zakharova N; Rivero A; Durant J; Ortega-Gonzalez E; Lathouwers E; Janssen K; Ouwerkerk-Mahadevan S; Witek J; González-García J
J Antimicrob Chemother; 2016 Jan; 71(1):244-50. PubMed ID: 26483516
[TBL] [Abstract][Full Text] [Related]
4. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
[TBL] [Abstract][Full Text] [Related]
5. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatment in HIV/HCV coinfection.
Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
[TBL] [Abstract][Full Text] [Related]
9. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
[TBL] [Abstract][Full Text] [Related]
10. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
Colombo M; Fernández I; Abdurakhmanov D; Ferreira PA; Strasser SI; Urbanek P; Moreno C; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Läuffer JM; Lonjon-Domanec I; Wedemeyer H
Gut; 2014 Jul; 63(7):1150-8. PubMed ID: 24201995
[TBL] [Abstract][Full Text] [Related]
11. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Colombo M; Strasser S; Moreno C; Abrao Ferreira P; Urbanek P; Fernández I; Abdurakmonov D; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Lonjon-Domanec I; Wedemeyer H
J Hepatol; 2014 Nov; 61(5):976-83. PubMed ID: 24946280
[TBL] [Abstract][Full Text] [Related]
12. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Macías J; Rivero A
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Genebat M; Vera F; Hernández-Quero J; Domingo P; Guardiola JM; Martínez-Madrid O; Martínez L; de la Llana FG; Sánchez-Villegas J; Alvarez H; Mariño A; Lluch JF; Martínez-Pérez MA; Marín J; Ruiz-Mateos E; Leal M
Antiviral Res; 2014 Apr; 104():59-61. PubMed ID: 24491797
[TBL] [Abstract][Full Text] [Related]
15. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
Martel-Laferrière V; Brinkley S; Bichoupan K; Posner S; Stivala A; Perumalswami P; Schiano T; Sulkowski M; Dieterich D; Branch A
HIV Med; 2014 Feb; 15(2):108-15. PubMed ID: 24025147
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
[TBL] [Abstract][Full Text] [Related]
17. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM;
Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266
[TBL] [Abstract][Full Text] [Related]
18. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
[TBL] [Abstract][Full Text] [Related]
19. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
Beste LA; Green PK; Ioannou GN
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
